|
|
|
| Clinical effect of Guizhi Decoction combined with Salmeteroticasone Aerosol in the treatment of bronchial asthma |
| CHEN Li-sheng XU Ai-ting FEI Chun-xian |
| Department of Geriatrics,Yangjiang People′s Hospital,Guangdong Province,Yangjiang 529500,China |
|
|
|
|
Abstract Objective To observe the clinical effect of Guizhi Decoction combined with Salmeteroticasone Aerosol in the treatment of bronchial asthma.Methods A total of 80 patients with bronchial asthma admitted to our hospital from June 2017 to February 2019 were selected as the subjects of this study.The patients were randomly divided into control group and observation group,with 40 cases in each group.The control group was treated with Salmeteroticasone Aerosol alone.On the basis of the treatment of the control group,patients in the observation group were given Guizhi Decoction,2 doses/d,once in the morning and once in the evening.The clinical treatment effect,the disappearance time of wheezing symptoms,levels of pulmonary function indexs (forced expiratory volume in 1 second [FEV1],forced vital capacity [FVC],FEV1/FVC) before and after treatment,and occurrence of adverse reactions in the two groups were compared.Results The total effective rate of the observation group was 95.00%,which was higher than that of the control group (80.00%),and the difference was statistically significant (P<0.05).The disappearance time of wheezing symptoms in the observation group was (5.3±0.6) d,which was shorter than that in the control group for (7.6±0.7) d,and the difference was statistically significant (P<0.05).Before treatment,the levels of pulmonary function indexs (FEV1,FVC,FEV1/FVC) were compared between the two groups,and the differences were not statistically significant (P>0.05).After treatment,the levels of pulmonary function indexs (FEV1,FVC,FEV1/FVC) in the observation group were higher than those in the control group,and the differences were statistically significant (P<0.05).After treatment,the levels of pulmonary function indexs (FEV1,FVC,FEV1/FVC) in the observation group were higher than those before treatment,and the differences were statistically significant (P<0.05).During the treatment period,4 cases (10.00%) of adverse reactions occurred during treatment in the control group and 2 cases (5.00%) in the observation group.There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion Guizhi Decoction combined with Salmeteroticasone Aerosol has a significant effect on bronchial asthma,which can shorten the time of patients′ wheezing symptoms,improve patients′ pulmonary function and reduce adverse reactions.Therefore,it is worthy of clinical application and promotion.
|
|
|
|
|
|
| [1] |
孙健，沈巨信.呼出气一氧化氮与支气管哮喘-慢性阻塞性肺疾病重叠关系的研究进展[J/OL].中国全科医学，2019，3（15）：1879-1883.
|
| [2] |
余春梅，陈聪，王斌，等.维生素A辅助沙美特罗替卡松粉吸入剂治疗儿童哮喘疗效观察[J].儿科药学杂志，2019，6（5）：16-19.
|
| [3] |
中华医学会呼吸病学分会哮喘学组.支气管哮喘防治指南（2016年版）[J].中华结核和呼吸杂志，2016，39（9）：675-697.
|
| [4] |
张君雪，李树民，马雪梅，等.HMGB1、FeNO在支气管哮喘中表达意义的研究[J].临床肺科杂志，2019，24（4）：708-710.
|
| [5] |
唐元春，李颖洁，屠春林.支气管哮喘诊疗进展[J].中国保健营养，2018，28（29）：63.
|
| [6] |
李敏，魏朝霞.沙美特罗替卡松和糖皮质激素气雾剂治疗小儿哮喘的效果比较[J].医学综述，2017，23（17）：3529-3532.
|
| [7] |
杜焰家，张伟强，郭俊华.沙美特罗替卡松气雾剂在治疗支气管哮喘中的效果及对FEV1和PEF的影响[J].中国当代医药，2016，23（1）：163-165.
|
| [8] |
刘温丽，史艳平，张金虎.支气管哮喘的中医研究进展[J].陕西中医，2018，39（6）：812-814.
|
| [9] |
吴强.加味二麻四仁汤联合穴位敷贴治疗气虚痰郁型支气管哮喘慢性持续期的临床观察[J].中医药信息，2019，36（2）：40-43.
|
| [10] |
王雪慧，田梓廷，李竹英.支气管哮喘慢性持续期中医分型[J].河南中医，2018，38（4）：508-510.
|
| [11] |
刘建秋，张霞，王雪慧.温阳补肾类中药单体治疗支气管哮喘实验述评[J].中华中医药学刊，2017，35（9）：2222-2224.
|
| [12] |
刘永平.论痰瘀是支气管哮喘的根本[J].辽宁中医杂志，2012，39（4）：664-665.
|
| [13] |
王中云，宋文华，阳曦，等.补肺固元膏治疗支气管哮喘缓解期36例临床观察[J].湖南中医杂志，2018，34（6）：50-51.
|
| [14] |
周新，张旻.应重视支气管哮喘的几个特殊问题[J].中华结核和呼吸杂志，2019，42（3）：164-166.
|
| [15] |
刘杰，沈洁，盛昭园.柴胡桂枝汤现代应用研究[J].中医文献杂志，2019，37（1）：62-65.
|
|
|
|
